LIXT earnings analysis
What we found in LIXT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lixte Biotechnology Holdings, Inc. has not yet realized revenue and continued to incur significant losses with a net loss of $1,987,608 for Q1 2026, up from a net loss of $709,555 in Q1 2025. The company is engaged in early-stage clinical trials and reports substantial management and development costs. There are significant concerns regarding the company's ability to continue as a going concern over the next 12 months due to the lack of capital and revenue generation.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue Generation
- Lixte reported no revenue for the three months ended March 31, 2026, consistent with zero revenue from the same period in 2025.
- Net Loss Increases
- The net loss for Q1 2026 was $1,987,608, significantly higher than the $709,555 net loss in Q1 2025.
- R&D Costs Surge
- Research and development costs increased to $333,376 from $91,457 in the previous year, a 265% increase.
- G&A Costs Spike
- General and administrative expenses rose to $1,654,031, compared to $615,483 in Q1 2025, an increase of 169%.
- Cash Decrease
- Cash decreased by $1,856,222 during the quarter, with $3,250,650 cash remaining as of March 31, 2026.
- Working Capital Decline
- The company's working capital decreased to $2,182,816 from $3,845,268 at the end of 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Doubt on Going Concern
- Management concluded there is substantial doubt regarding the company's ability to continue as a going concern for at least 12 months after the report date.
- Reliance on Equity Financing
- The company is heavily dependent on periodic access to equity capital, increasing financial instability risk.
- Adverse Clinical Trial Events
- Recent SAEs in clinical trials raised concerns which could lead to trial holds, affecting future development plans.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.18
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads worse than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LIXT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever